World's Best Scientists 2026 revealed!

D-Index & Metrics

Psychology

D-Index
38
Citations
5117
World Ranking
8938
National Ranking
4737

Overview

Adam Bisaga is affiliated with Columbia University in the United States and focuses research efforts primarily within the field of Medicine. Their work spans several subfields including Public Health, Environmental and Occupational Health, Epidemiology, Cellular and Molecular Neuroscience, Psychiatry and Mental Health, and Pharmacology. The research topics they address predominantly relate to Opioid Use Disorder Treatment, Substance Abuse Treatment and Outcomes, Neurotransmitter Receptor Influence on Behavior, Treatment of Major Depression, Attention Deficit Hyperactivity Disorder, Prenatal Substance Exposure Effects, and the intersection of HIV, Drug Use, and Sexual Risk.

Bisaga's publication record features contributions mainly to journals such as Drug and Alcohol Dependence, Addiction, The Canadian Journal of Psychiatry, Journal of Dental Education, and Psychopharmacology. Their notable recent academic papers include:

  • Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis (2020, Psychopharmacology)
  • Quetiapine treatment for cannabis use disorder (2020, Drug and Alcohol Dependence)
  • Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder (2021, Alcoholism Clinical and Experimental Research)
  • Medical Student Attitudes Toward Substance Use Disorders Before and After a Skills-Based Screening, Brief Intervention, and Referral to Treatment (SBIRT) Curriculum (2020, Advances in Medical Education and Practice)
  • Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk (2023, BMJ Mental Health)

Frequent collaborators in Bisaga's research include Edward V. Nunes, Frances R. Levin, Matisyahu Shulman, Mei-Chen Hu, and Vítor S. Tardelli. Collaboration patterns indicate a concentration on substance use and treatment-related studies.

Their scientific output demonstrates a focus on clinical and translational research related to substance use disorders, pharmacological treatment options, and behavioral health interventions. Bisaga has participated in advancing understanding of medication treatments for stimulant, cannabis, and opioid use disorders, as well as examining attitudes and educational approaches toward substance use disorders among medical students.

Best Publications

  • Cognitive deficits predict low treatment retention in cocaine dependent patients

    Efrat Aharonovich;Deborah S. Hasin;Adam C. Brooks;Xinhua Liu

  • Development of a Cascade of Care for responding to the opioid epidemic

    Arthur Robin Williams;Arthur Robin Williams;Edward V. Nunes;Edward V. Nunes;Adam Bisaga;Adam Bisaga;Frances R. Levin;Frances R. Levin

  • Cerebral glucose metabolism in women with panic disorder

    Adam Bisaga;Jack L. Katz;Angelo Antonini;C. Eugene Wright

  • Developing an opioid use disorder treatment cascade: A review of quality measures.

    Arthur Robin Williams;Edward V. Nunes;Adam Bisaga;Harold A. Pincus

  • The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans.

    Adam Bisaga;Sandra D. Comer;Amie S. Ward;Piotr Popik

  • Cognition, commitment language, and behavioral change among cocaine-dependent patients

    Efrat Aharonovich;Paul C. Amrhein;Adam Bisaga;Edward V. Nunes

  • Sex differences and hormonal influences on response to cold pressor pain in humans.

    William J. Kowalczyk;Suzette M. Evans;Adam M. Bisaga;Maria A. Sullivan

  • In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-d-aspartate (NMDA) antagonists

    Adam Bisaga;Piotr Popik

  • Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis

    Vitor S Tardelli;Adam Bisaga;Felipe B Arcadepani;Gilberto Gerra

  • Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial ☆

    Frances R. Levin;John J. Mariani;Martina Pavlicova;Daniel Brooks

  • A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

    Frances R. Levin;John Mariani;Daniel J. Brooks;Martina Pavlicova

  • A randomized placebo-controlled trial of gabapentin for cocaine dependence

    Adam Bisaga;Efrat Aharonovich;Fatima Garawi;Frances R. Levin

  • Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

    Maria Sullivan;Adam Bisaga;Martina Pavlicova;C. Jean Choi

  • Extended Release Mixed Amphetamine Salts and Topiramate for Cocaine Dependence: A Randomized Controlled Trial

    John J. Mariani;Martina Pavlicova;Adam Bisaga;Edward V. Nunes

  • The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone

    Adam Bisaga;Maria A. Sullivan;Andrew Glass;Kaitlyn Mishlen

  • Interaction between naltrexone and oral THC in heavy marijuana smokers.

    Margaret Haney;Adam Bisaga;Richard W. Foltin

  • Acute interaction of baclofen in combination with alcohol in heavy social drinkers.

    Suzette M. Evans;Adam Bisaga

  • A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.

    Maria A. Sullivan;Adam Bisaga;Martina Pavlicova;Kenneth M. Carpenter

  • Reinstatement of morphine-conditioned reward is blocked by memantine.

    Piotr Popik;Malgorzata Wrobel;Adam Bisaga

  • Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder

    Adam Bisaga;Wojciech Danysz;Richard W. Foltin

Frequent Co-Authors

Frances R. Levin
Frances R. Levin Columbia University
Richard W. Foltin
Richard W. Foltin Columbia University
Deborah S. Hasin
Deborah S. Hasin Columbia University
Aimee N. C. Campbell
Aimee N. C. Campbell Columbia University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in psychology opens up numerous opportunities, both in traditional and online learning formats. Many students start with a bachelor's degree in psychology before pursuing online master's or doctoral programs. These advanced degrees allow for specialization in clinical counseling, organizational psychology, or mental health therapy.

Becoming a practicing, licensed therapist requires meeting specific state requirements. For example, those interested in practicing in Kentucky should review the Louisville licensed therapist requirements. Similarly, potential counselors planning to work in Texas can find details about becoming a licensed therapist in Lubbock.

Licensing requirements vary by location—candidates in Wisconsin should review the licensed therapist requirements in Madison, while those aiming to practice in Tennessee can refer to guidelines on how to become a licensed therapist in Memphis.

Ultimately, earning an online degree can provide flexibility, but aspiring therapists must ensure their program meets the state's licensure requirements for the region where they plan to practice.

Best Scientists Citing Adam Bisaga

Trending Scientists

Recently Published Articles